Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
NCT00179673Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2005
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of lenalidomide in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Celgene Corporation. Started Jun 2005; status: completed.
02
Drugs
lenalidomide
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT00179673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00179673.